Takeda said its first quarter of fiscal 2026 was broadly in line with guidance, supported by resilient demand across core in-line brands and steady progress on late-stage launch preparations and pipeline development. The company reported revenue of JPY 1,219.9 billion, up 10.2% year on year on an actual exchange rate basis, while core operating profit rose 11.5% and reported operating profit increased 9.1%.
Takeda said the strength of its core portfolio largely offset the impact of VYVANSE generic erosion, helping keep the company on track for its full-year commitments. Core EPS rose 1.5% at actual exchange rates, while adjusted free cash flow came to JPY 68.6 billion. The company left its FY2026 forecast and management guidance unchanged.
Chief Executive Officer Julie Kim said the quarter reflected disciplined execution and operational momentum, and that the company’s transformation program is helping fund its highest priorities. Chief Financial Officer Milano Furuta said Takeda’s first-quarter performance tracked consistently with guidance and that operating expense savings are being reinvested to support future growth.
Takeda said launch preparations for three key late-stage assets are progressing on schedule. ORZEYFUL, also known as oveporexton, recently received its first approval in China, with U.S. and Japan applications still under review. The company also said rusfertide, a potential first-in-class treatment for polycythemia vera, has received U.S. FDA Priority Review, and zasocitinib posted positive topline Phase 3 results in psoriasis.
Takeda said its pipeline progress is building the foundation for future growth, with expected launches in the second half of 2026 and early 2027. The company plans to hold a Capital Markets Day in Tokyo on Dec. 11, 2026.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!